NURIX THERAPEUTICS INC (NRIX) Stock Income Statement
NASDAQ:NRIX - Nasdaq - US67080M1036 - Common Stock - Currency: USD
| TTM (2025-5-31) | 2024 (2024-11-30) | 2023 (2023-11-30) | 2022 (2022-11-30) | 2021 (2021-11-30) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 88.38M | 54.55M | 76.99M | 38.63M | 29.75M | |||
| Operating Expenses | 318.83M | 267.58M | 232.05M | 222.49M | 147.64M | |||
| Research and Development | 270.46M | 221.63M | 189.15M | 184.50M | 116.43M | |||
| Selling, General, and Administrative Expenses | 48.37M | 45.94M | 42.90M | 38.00M | 31.20M | |||
| Operating Income | -230.45M | -213.03M | -155.06M | -183.87M | -117.89M | |||
| Interest Income/Expense | 23.98M | 19.73M | 11.12M | 3.51M | 820.00K | |||
| Income Before Taxes | -206.47M | -193.30M | -143.95M | -180.36M | -117.06M | |||
| Income Tax | 850.00K | 270.00K | N/A | 0.00 | 130.00K | |||
| Net Income | -207.32M | -193.57M | -143.95M | -180.36M | -117.19M | |||
| EBITDA | -212.78M | -196.60M | -141.41M | -178.52M | -115.10M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -2.61 | -2.88 | -2.65 | -3.71 | -2.73 | |||
| Non GAAP EPS | -2.61 | -2.89 | -2.65 | -3.73 | -2.73 | |||
| Statistics | ||||||||
| Profit Margin | -234.58% | -354.85% | -186.98% | -466.89% | -393.92% | |||
| Operating Profit Margin | -260.75% | -390.52% | -201.41% | -475.98% | -396.27% | |||
All data in USD